The article tells about a comparative evaluation of lipid correction and remodeling effects of statin monotherapy and its fixed combination with ezetimibe on the left ventricular myocardium, intima-media thickness (IMT) and C-reactive protein (CRP) in men and women with metabolic syndrome (MS). The combination simvastatin + ezetimibe was more effective in women, resulting both in greater number of patients achieving the target level of LDL cholesterol, and the degree of positive change in lipid profile and IMT. Hypolipidemic and anti-inflammatory effects are comparable in men and women with MS who took simvastatin. Therapy with simvastatin or simvastatin + ezetimibe has a more marked anti-remodelling effect in women compared with men